Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics

Y Jin, M Liu, R Sa, H Fu, L Cheng, L Chen - Cancer Letters, 2020 - Elsevier
Due to a global increase in the incidence of thyroid cancer, numerous novel mouse models
were established to reveal thyroid cancer pathogenesis and test promising therapeutic …

Role of vandetanib in the management of medullary thyroid cancer

M Brassard, G Rondeau - Biologics: Targets and Therapy, 2012 - Taylor & Francis
Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation
therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma …

Predictive value of 18F-FDG PET in patients with advanced medullary thyroid carcinoma treated with vandetanib

RA Werner, JS Schmid, T Higuchi… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Therapeutic options in advanced medullary thyroid carcinoma (MTC) have markedly
improved since the introduction of tyrosine kinase inhibitors (TKIs). We aimed to assess the …

[HTML][HTML] Vandetanib versus cabozantinib in medullary thyroid carcinoma: A focus on anti-angiogenic effects in zebrafish model

S Carra, G Gaudenzi, A Dicitore, D Saronni… - International Journal of …, 2021 - mdpi.com
Medullary thyroid carcinoma (MTC) is a tumor deriving from the thyroid C cells. Vandetanib
(VAN) and cabozantinib (CAB) are two tyrosine kinase inhibitors targeting REarranged …

Evaluation of the Genisys4, a bench-top preclinical PET scanner

K Herrmann, M Dahlbom, D Nathanson… - Journal of Nuclear …, 2013 - Soc Nuclear Med
The Genisys4 is a small bench-top preclinical PET scanner designed to enable imaging in
biology, biochemistry, and pharmacology laboratories and imaging centers. Here, we …

[HTML][HTML] Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib

RA Werner, RA Bundschuh, T Higuchi, MS Javadi… - Endocrine, 2019 - Springer
Purpose The metabolically most active lesion in 2-deoxy-2-(18 F) fluoro-D-glucose (18 F-
FDG) PET/CT can predict progression-free survival (PFS) in patients with medullary thyroid …

Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib

M Tiseo, M Ippolito, M Scarlattei, P Spadaro… - Cancer chemotherapy …, 2014 - Springer
Abstract Background [18F] fluorodeoxyglucose (FDG)-PET is being evaluated as a tool for
the early detection of response to various targeted agents in solid tumors. The aim of this …

[PDF][PDF] Vandetanib therapy in medullary thyroid cancer

P Grabowski, F Briest, RP Baum, JJ Zaknun… - Drugs of …, 2012 - researchgate.net
SUMMARY The US Food and Drug Administration (FDA) approved vandetanib in April 2011
for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer …

[HTML][HTML] The scope and potentials of functional radionuclide imaging towards advancing personalized medicine in oncology: emphasis on PET-CT

S Basu - Discovery Medicine, 2012 - discoverymedicine.com
Behavioral heterogeneity within a given patient cohort has been a major challenge in
clinical practice and is probably most prominently observed in the field of oncology. This has …

Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma

S De Luca, R Fonti, L Camera, B Salvatore… - Annals of nuclear …, 2016 - Springer
Objective The aim of our study was to determine the role of fluorine-18 fluorodeoxyglucose
positron emission tomography/computed tomography (18 F-FDG-PET/CT) and indium-111 …